Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor α and carnitine palmitoyl acyl-CoA transferase 1A-Reference-Cited by-同舟云学术

Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor α and carnitine palmitoyl acyl-CoA transferase 1A

Published:2005 Issue:48 Volume:11 Page:7591
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Cheng Yang

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference36 articles.

1. The Scientific Challenge of Hepatitis C

2. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

3. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C

4. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C

5. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink;Pathogens;2024-01-10

2. Transcriptome analysis reveals the host immune response upon LMBV infection in largemouth bass (Micropterus salmoides);Fish & Shellfish Immunology;2023-06

3. Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight;Hepatology Research;2023-04-04

4. Hepatic PPARα Is Destabilized by SIRT1 Deacetylase in Undernourished Male Mice;Frontiers in Nutrition;2022-03-28

5. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study;Endocrine, Metabolic & Immune Disorders - Drug Targets;2022-01